Abstract: The invention relates to pharmaceutical compositions comprising a PCSK9 inhibitor, such as an EGF(A) peptide, and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid. The invention further relates to processes for the preparation of such compositions, and their use in medicine.
| # | Name | Date |
|---|---|---|
| 1 | 202247009361.pdf | 2022-02-22 |
| 2 | 202247009361-STATEMENT OF UNDERTAKING (FORM 3) [22-02-2022(online)].pdf | 2022-02-22 |
| 3 | 202247009361-SEQUENCE LISTING(PDF) [22-02-2022(online)].pdf | 2022-02-22 |
| 4 | 202247009361-SEQUENCE LISTING [22-02-2022(online)].txt | 2022-02-22 |
| 5 | 202247009361-PRIORITY DOCUMENTS [22-02-2022(online)].pdf | 2022-02-22 |
| 6 | 202247009361-POWER OF AUTHORITY [22-02-2022(online)].pdf | 2022-02-22 |
| 7 | 202247009361-FORM 1 [22-02-2022(online)].pdf | 2022-02-22 |
| 8 | 202247009361-DRAWINGS [22-02-2022(online)].pdf | 2022-02-22 |
| 9 | 202247009361-DECLARATION OF INVENTORSHIP (FORM 5) [22-02-2022(online)].pdf | 2022-02-22 |
| 10 | 202247009361-COMPLETE SPECIFICATION [22-02-2022(online)].pdf | 2022-02-22 |
| 11 | 202247009361-FORM 18 [24-02-2022(online)].pdf | 2022-02-24 |
| 12 | 202247009361-FER.pdf | 2022-03-31 |
| 13 | 202247009361-Proof of Right [05-07-2022(online)].pdf | 2022-07-05 |
| 14 | 202247009361-Information under section 8(2) [18-08-2022(online)].pdf | 2022-08-18 |
| 15 | 202247009361-FORM 3 [18-08-2022(online)].pdf | 2022-08-18 |
| 16 | 202247009361-FORM 4(ii) [20-09-2022(online)].pdf | 2022-09-20 |
| 17 | 202247009361-RELEVANT DOCUMENTS [28-09-2022(online)].pdf | 2022-09-28 |
| 1 | SearchHistoryE_30-03-2022.pdf |